FTRE
Price
$17.37
Change
-$1.03 (-5.60%)
Updated
Jan 13, 04:59 PM (EDT)
Capitalization
1.7B
62 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$31.53
Change
-$1.27 (-3.87%)
Updated
Jan 13, 04:59 PM (EDT)
Capitalization
2.55B
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FTRE vs SYRE

Header iconFTRE vs SYRE Comparison
Open Charts FTRE vs SYREBanner chart's image
Fortrea Holdings
Price$17.37
Change-$1.03 (-5.60%)
Volume$34.46K
Capitalization1.7B
Spyre Therapeutics
Price$31.53
Change-$1.27 (-3.87%)
Volume$6.72K
Capitalization2.55B
FTRE vs SYRE Comparison Chart in %
FTRE
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FTRE vs. SYRE commentary
Jan 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTRE is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 14, 2026
Stock price -- (FTRE: $18.40 vs. SYRE: $32.80)
Brand notoriety: FTRE and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FTRE: 128% vs. SYRE: 79%
Market capitalization -- FTRE: $1.7B vs. SYRE: $2.55B
FTRE [@Biotechnology] is valued at $1.7B. SYRE’s [@Biotechnology] market capitalization is $2.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $116.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FTRE’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • FTRE’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, FTRE is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FTRE’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • FTRE’s TA Score: 3 bullish, 5 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both FTRE and SYRE are a bad buy in the short-term.

Price Growth

FTRE (@Biotechnology) experienced а +10.71% price change this week, while SYRE (@Biotechnology) price change was +9.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.80%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +42.28%.

Reported Earning Dates

FTRE is expected to report earnings on Mar 16, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+4.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($2.55B) has a higher market cap than FTRE($1.7B). FTRE YTD gains are higher at: 6.667 vs. SYRE (0.122). SYRE has higher annual earnings (EBITDA): -223.64M vs. FTRE (-852.7M). SYRE has more cash in the bank: 486M vs. FTRE (131M). SYRE has less debt than FTRE: SYRE (0) vs FTRE (1.19B). FTRE has higher revenues than SYRE: FTRE (2.76B) vs SYRE (0).
FTRESYREFTRE / SYRE
Capitalization1.7B2.55B67%
EBITDA-852.7M-223.64M381%
Gain YTD6.6670.1225,460%
P/E RatioN/A1.72-
Revenue2.76B0-
Total Cash131M486M27%
Total Debt1.19B0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
83
SEASONALITY SCORE
1..100
49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FTRESYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 26 days ago
75%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
FTRE
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIGBX46.110.29
+0.63%
American Funds Intl Gr and Inc R2
TGRIX14.240.08
+0.56%
American Century International Gr I
LSPIX5.560.03
+0.54%
LoCorr Spectrum Income I
PURCX20.110.05
+0.25%
PGIM Global Real Estate C
APHLX14.82-0.04
-0.27%
Artisan Value Institutional

FTRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FTRE has been loosely correlated with BEAM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FTRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FTRE
1D Price
Change %
FTRE100%
+5.81%
BEAM - FTRE
45%
Loosely correlated
+22.29%
SYRE - FTRE
45%
Loosely correlated
+7.15%
TECH - FTRE
43%
Loosely correlated
+1.31%
ALGS - FTRE
41%
Loosely correlated
-3.22%
NTLA - FTRE
41%
Loosely correlated
+10.12%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+7.15%
ORKA - SYRE
58%
Loosely correlated
+10.16%
BEAM - SYRE
57%
Loosely correlated
+22.29%
XNCR - SYRE
57%
Loosely correlated
+2.02%
RGNX - SYRE
57%
Loosely correlated
+3.36%
APGE - SYRE
56%
Loosely correlated
-0.44%
More